BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37549739)

  • 41. MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway.
    Yao Y; Dou C; Lu Z; Zheng X; Liu Q
    Cell Physiol Biochem; 2015; 35(3):983-96. PubMed ID: 25660117
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The critical role of dysregulated Hh-FOXM1-TPX2 signaling in human hepatocellular carcinoma cell proliferation.
    Wang Y; Wang H; Yan Z; Li G; Hu G; Zhang H; Huang D; Wang Y; Zhang X; Yan Y; Lu Q; Cheng M; Luo S
    Cell Commun Signal; 2020 Jul; 18(1):116. PubMed ID: 32723329
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/β-catenin signaling.
    Zhao YR; Wang JL; Xu C; Li YM; Sun B; Yang LY
    Clin Sci (Lond); 2019 Jul; 133(14):1645-1662. PubMed ID: 31278131
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition.
    Xiao S; Chang RM; Yang MY; Lei X; Liu X; Gao WB; Xiao JL; Yang LY
    Hepatology; 2016 Apr; 63(4):1256-71. PubMed ID: 26698646
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The 14-3-3σ protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 signaling pathway.
    Song J; Liu Y; Liu F; Zhang L; Li G; Yuan C; Yu C; Lu X; Liu Q; Chen X; Liang H; Ding Z; Zhang B
    Theranostics; 2021; 11(3):996-1015. PubMed ID: 33391517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth.
    Luo T; Zhang SG; Zhu LF; Zhang FX; Li W; Zhao K; Wen XX; Yu M; Zhan YQ; Chen H; Ge CH; Gao HY; Wang L; Yang XM; Li CY
    J Exp Clin Cancer Res; 2019 Mar; 38(1):130. PubMed ID: 30885237
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MicroRNA-451: epithelial-mesenchymal transition inhibitor and prognostic biomarker of hepatocelluar carcinoma.
    Huang JY; Zhang K; Chen DQ; Chen J; Feng B; Song H; Chen Y; Zhu Z; Lu L; De W; Wang R; Chen LB
    Oncotarget; 2015 Jul; 6(21):18613-30. PubMed ID: 26164082
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1.
    Ozen E; Gozukizil A; Erdal E; Uren A; Bottaro DP; Atabey N
    PLoS One; 2012; 7(8):e42717. PubMed ID: 22912725
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.
    Buurman R; Gürlevik E; Schäffer V; Eilers M; Sandbothe M; Kreipe H; Wilkens L; Schlegelberger B; Kühnel F; Skawran B
    Gastroenterology; 2012 Sep; 143(3):811-820.e15. PubMed ID: 22641068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts.
    Zhou Y; Ren H; Dai B; Li J; Shang L; Huang J; Shi X
    J Exp Clin Cancer Res; 2018 Dec; 37(1):324. PubMed ID: 30591064
    [TBL] [Abstract][Full Text] [Related]  

  • 52. C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway.
    Zhao M; Wang Y; Liu Y; Zhang W; Liu Y; Yang X; Cao Y; Wang S
    Cancer Biol Ther; 2019; 20(12):1430-1442. PubMed ID: 31441380
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cancer-associated fibroblasts promote the stemness of CD24
    Li Y; Wang R; Xiong S; Wang X; Zhao Z; Bai S; Wang Y; Zhao Y; Cheng B
    J Mol Med (Berl); 2019 Feb; 97(2):243-255. PubMed ID: 30564864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway.
    Liu Y; Tan J; Ou S; Chen J; Chen L
    Invest New Drugs; 2020 Feb; 38(1):60-69. PubMed ID: 30929159
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development.
    Tu T; Budzinska MA; Maczurek AE; Cheng R; Di Bartolomeo A; Warner FJ; McCaughan GW; McLennan SV; Shackel NA
    Int J Mol Sci; 2014 May; 15(6):9422-58. PubMed ID: 24871369
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diospyros kaki leaves inhibit HGF/Met signaling-mediated EMT and stemness features in hepatocellular carcinoma.
    Ko H; Huh G; Jung SH; Kwon H; Jeon Y; Park YN; Kim YJ
    Food Chem Toxicol; 2020 Aug; 142():111475. PubMed ID: 32522589
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Induction of tumor initiation is dependent on CD44s in c-Met⁺ hepatocellular carcinoma.
    Dang H; Steinway SN; Ding W; Rountree CB
    BMC Cancer; 2015 Mar; 15():161. PubMed ID: 25886575
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regulation of a TGF-β1-CD147 self-sustaining network in the differentiation plasticity of hepatocellular carcinoma cells.
    Wu J; Lu M; Li Y; Shang YK; Wang SJ; Meng Y; Wang Z; Li ZS; Chen H; Chen ZN; Bian H
    Oncogene; 2016 Oct; 35(42):5468-5479. PubMed ID: 27041581
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.
    Wang F; Hou W; Chitsike L; Xu Y; Bettler C; Perera A; Bank T; Cotler SJ; Dhanarajan A; Denning MF; Ding X; Breslin P; Qiang W; Li J; Koleske AJ; Qiu W
    Gastroenterology; 2020 Jul; 159(1):289-305.e16. PubMed ID: 32171747
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
    Xiang Q; Chen W; Ren M; Wang J; Zhang H; Deng DY; Zhang L; Shang C; Chen Y
    Clin Cancer Res; 2014 Jun; 20(11):2959-70. PubMed ID: 24700742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.